Mar 13, 2020
Spherix Completes Name Change to AIkido Pharma Inc.
Mar 09, 2020
Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market
Mar 06, 2020
Treatment for Coronavirus Optioned by Spherix
Mar 03, 2020
Spherix Executes Machine Learning Scientific Research Agreement
Mar 03, 2020
Spherix Announces Pricing of $7.5 Million Public Offering
Feb 25, 2020
Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference
Feb 23, 2020
Spherix Announces a Special Dividend Distribution
Jan 21, 2020
Spherix Launches Newly Redesigned Website
Dec 10, 2019
Spherix Announces the Closing of CBM BioPharma Transaction
Nov 27, 2019
Spherix Notes Additional Patent Coverage Granted
Oct 17, 2019
Spherix Highlights ValuEngine Upgrade to 'Buy' Rating
Sep 25, 2019
Spherix Issues Update to Shareholders Regarding Planned Dividend Distribution
Sep 17, 2019
University of Maryland, Baltimore Grants Spherix Exclusive Option to License Anthrax Based Ovarian Cancer Drug PrAg-PAS
Sep 11, 2019
Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky
Sep 09, 2019
Spherix Announces Results of Special Meeting of Shareholders
May 16, 2019
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Apr 02, 2019
Spherix Issues Letter to Shareholders
Mar 12, 2019
Spherix Announces Filing of its Annual Report on Form 10-K, Records $7.5 Million One Time Gain
Nov 27, 2018
Spherix Announces Preclinical Pancreatic Cancer Treatment Study Moving Forward
Oct 29, 2018
Spherix Announces the Addition of Dr. Rana Quraishi to Company's Advisory Board